<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02381470</url>
  </required_header>
  <id_info>
    <org_study_id>Faropenem_TB</org_study_id>
    <nct_id>NCT02381470</nct_id>
  </id_info>
  <brief_title>Early Bactericidal Activity Study of Faropenem(With Amoxicillin/Clavulanic Acid)in Patients With Pulmonary Tuberculosis</brief_title>
  <official_title>Trial of Faropenem (in Combination With Amoxicillin/Clavulanic Acid) in Patients With Pulmonary Tuberculosis: Measurement of Early Bactericidal Activity, Whole Blood Bactericidal Activity and Effects on Novel Biomarkers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National University Hospital, Singapore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National University Hospital, Singapore</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Faropenem is an oral penem, closely related to the carbapenem class that is used for the
      treatment of bacterial infections. It has in vitro activity against Mycobacterium
      tuberculosis and this trial aims to determine the activity of faropenem with
      amoxicillin/clavulanic acid in patients with pulmonary TB.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase II randomised, controlled, open-label, early bactericidal activity trial in
      which 28 patients between the ages of 18 and 70 with newly-diagnosed smear positive pulmonary
      TB, who have not yet started standard TB therapy will be recruited.

      Patients will be randomised to one of 3 arms - Arm A: Faropenem 400mg with
      amoxicillin/clavulanic acid (500mg/125mg), each three times daily for 5 days (n=12) Arm B:
      Pyrazinamide 2g (1.5g if weight &lt;50kg) once daily for 5 days (n=8) Arm C: Isoniazid 300mg
      once daily for 5 days (n=8) Following the 5 days of study medication the study will end and
      patients will change to standard combination TB therapy and enter normal clinical follow-up.

      In addition to the CFU and TTP related primary and secondary outcome measures, other outcomes
      measures such as the pharmacokinetics of faropenem, change in RPF-dependent colony counts,
      change of expression of select signature Mtb genes in sputum transcriptome, changes in host
      transcriptome and change in host immune profile will be determined.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2017</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of change of time to positivity (TTP) in liquid culture from day 0 to day 5</measure>
    <time_frame>5 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of change of TTP in liquid culture from day 0 to day 2</measure>
    <time_frame>2 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CFU/ml in solid culture from Day 0 to Day 5</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CFU/ml in solid culture from Day 0 to Day 2</measure>
    <time_frame>2 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative bactericidal activity (WBA) at Day 2</measure>
    <time_frame>2 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Tuberculosis</condition>
  <arm_group>
    <arm_group_label>Faropenem+amoxicillin/clavulanic acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Faropenem 400mg with amoxicillin/clavulanic acid (500mg/125mg) each three times daily for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pyrazinamide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pyrazinamide 2g (1.5g if weight &lt;50kg) once daily for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Isoniazid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Isoniazid 300mg once daily for 5 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Faropenem</intervention_name>
    <description>400mg Faropenem</description>
    <arm_group_label>Faropenem+amoxicillin/clavulanic acid</arm_group_label>
    <other_name>Farobact</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amoxicillin/clavulanic acid</intervention_name>
    <description>500mg Amoxicillin/ 125mg clavulanic acid</description>
    <arm_group_label>Faropenem+amoxicillin/clavulanic acid</arm_group_label>
    <other_name>Augmentin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pyrazinamide</intervention_name>
    <description>2g pyrazinamide</description>
    <arm_group_label>Pyrazinamide</arm_group_label>
    <other_name>PZA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isoniazid</intervention_name>
    <description>300mg isoniazid</description>
    <arm_group_label>Isoniazid</arm_group_label>
    <other_name>INH</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Aged 18 to 70 years

          2. Clinical features compatible with pulmonary TB

          3. Sputum smear graded at least 1 +

          4. Estimated to be producing at least 5ml of sputum per day

          5. Willing to comply with study procedures and able to provide written informed consent.

        Exclusion Criteria:

          1. Suspected miliary TB or TB meningitis

          2. Patients receiving any TB treatment within the previous 6 months

          3. Patients too ill to tolerate a 5-day delay in standard therapy

          4. Concurrent bacterial pneumonia

          5. Known hypersensitivity to beta-lactam drugs (penicillins, carbapanems) or to other
             study drugs (isoniazid, pyrazinamide)

          6. Estimated creatinine clearance &lt; 80 ml/min on screening blood test, calculated using
             Cockcroft-Gault formula

          7. ALT &gt; 2.5 times upper limit of normal on screening blood test.

          8. Women who are currently pregnant or breastfeeding.

          9. Any other significant condition that would, in the opinion of the investigator,
             compromise the patient's safety or outcome in the trial.

         10. Participation in other clinical intervention trial or research protocol (participation
             in other studies that do not involve an intervention may be allowed, but this must be
             discussed and approved by the Chief Investigator)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicholas Paton</last_name>
    <role>Study Chair</role>
    <affiliation>National University Hospital, Singapore</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Meera Gurumurthy</last_name>
    <phone>+65 6772 7861</phone>
    <email>meera@nuhs.edu.sg</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pang Yan</last_name>
    <phone>+65 6772 7861</phone>
    <email>yan_pang@nuhs.edu.sg</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Lung Center Philippines</name>
      <address>
        <city>Manila</city>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vincent Balanag</last_name>
    </contact>
    <investigator>
      <last_name>Vincent Balanag</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Philippines Tuberculosis Society (Quezon Institute)</name>
      <address>
        <city>Manila</city>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jubert Benedicto</last_name>
    </contact>
    <investigator>
      <last_name>Jubert Benedicto</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Changi General Hospital</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Augustine Tee</last_name>
    </contact>
    <investigator>
      <last_name>Augustine Tee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National University Hospital, Singapore</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Meera Gurumurthy</last_name>
      <phone>+65 6772 7861</phone>
      <email>meera@nuhs.edu.sg</email>
    </contact>
    <investigator>
      <last_name>Nicholas Paton</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Philippines</country>
    <country>Singapore</country>
  </location_countries>
  <removed_countries>
    <country>Malaysia</country>
  </removed_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 2, 2015</study_first_submitted>
  <study_first_submitted_qc>March 5, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 6, 2015</study_first_posted>
  <last_update_submitted>March 30, 2017</last_update_submitted>
  <last_update_submitted_qc>March 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Tuberculosis, Pulmonary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Isoniazid</mesh_term>
    <mesh_term>Pyrazinamide</mesh_term>
    <mesh_term>Clavulanic Acids</mesh_term>
    <mesh_term>Clavulanic Acid</mesh_term>
    <mesh_term>beta-Lactams</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

